India Supreme Court: Kishan Chand Jain Cancer Medicine Pricing Fraud, 10x MRP Gap

• The Supreme Court of India recently criticized the significant price disparity between the Price to Retailer (PTR) and Maximum Retail Price (MRP) of essential cancer medicines.
• In the case of Kishan Chand Jain v. Union of India, which was disposed of in October 2023, Justices Vikram Nath and Sandeep Mehta cited an example where a cancer drug with a ₹2,700 PTR was sold at an MRP of ₹27,000, calling it "daylight robbery."
• The Court expressed concern over the absence of effective price-control mechanisms for life-saving drugs in India.
• Inflated pricing structures were identified as enabling systemic fraud on public funds, particularly through reimbursement under schemes like Ayushman Bharat.
• The Supreme Court highlighted the "absolute silence" of regulatory authorities regarding these price discrepancies, deeming it a "clear-cut case of fraud."

Hospitals, purchasing medicines at these elevated prices, then seek reimbursement from the government, effectively turning the taxpayer's money into a conduit for what the Court explicitly labeled a "clear-cut case of fraud."

The Supreme Court of India recently voiced grave concerns regarding the substantial disparities observed between the Price to Retailer (PTR) and the Maximum Retail Price (MRP) of critical life-saving medications, particularly those used in cancer treatment. In the case of Kishan Chand Jain v. Union of India, which was disposed of in October 2023, a bench comprising Justices Vikram Nath and Sandeep Mehta highlighted an alarming instance where an essential cancer medicine, sold by manufacturers to retailers for ₹2,700, carried an MRP of ₹27,000. This tenfold difference in pricing was unequivocally condemned by the Court, which characterized such practices as "daylight robbery" and an "absolute rampage and carnage" perpetrated against vulnerable patients. Justice Mehta specifically questioned how patients could be subjected to such exploitation when the initial cost to the retailer was significantly lower.

The Court's observations extended beyond individual instances of price gouging to a broader critique of the regulatory environment, pointing to a conspicuous absence of effective price-control mechanisms for essential drugs in India. This regulatory vacuum, according to the Justices, allows for the unchecked inflation of medicine prices. Furthermore, the Supreme Court underscored how these exorbitant pricing structures facilitate systemic fraud on public funds. When medical expenses are reimbursed under state-sponsored health initiatives, such as the Ayushman Bharat scheme, the inflated MRPs are paid out, ultimately burdening taxpayers. Hospitals, purchasing medicines at these elevated prices, then seek reimbursement from the government, effectively turning the taxpayer's money into a conduit for what the Court explicitly labeled a "clear-cut case of fraud." The Court also expressed surprise at the "absolute silence" of authorities tasked with addressing these discrepancies, hinting at underlying reasons without explicitly stating them.

The implications of such unchecked pricing practices are profound, affecting both individual patients battling severe illnesses and the national exchequer. The substantial difference between the cost of cancer medicine at the wholesale level and its retail price creates an immense financial burden on patients, many of whom are already in precarious health. Beyond the direct impact on patients, the Court's remarks highlight a critical vulnerability in public health schemes like Ayushman Bharat, where the absence of robust drug price control allows for the siphoning of taxpayer money through inflated reimbursements. This judicial scrutiny signals a potential turning point for Indian pharmaceutical pricing regulation, demanding greater accountability from drug manufacturers and distributors, and urging regulatory bodies to implement more stringent oversight to prevent future instances of what the Court termed "broad daylight dacoity" in the healthcare sector. The case of Kishan Chand Jain cancer medicine pricing fraud thus brings to the forefront the urgent need for comprehensive reforms in how essential drugs are priced and reimbursed across the country.

This Supreme Court observation signals heightened judicial scrutiny on pharmaceutical pricing in India, particularly for essential medicines and those reimbursed under government schemes like Ayushman Bharat. Lawyers advising drug manufacturers, distributors, or healthcare providers should alert clients to potential regulatory investigations, enforcement actions, or litigation risks related to price discrepancies and alleged fraud.

Source: Original reporting via Indian legal news outlets.